Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Klatskin Tumor 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 10Paclitaxel 8Taxes 6Nivolumab 4Cyclophosphamide 4Cisplatin 4Carboplatin 4Polymerase Chain Reaction 3Irinotecan 3Interleukin-12 Subunit p35 3Docetaxel 3Bevacizumab 3sargramostim 2lenvatinib 2aldesleukin 2aflibercept 2Trastuzumab 2SS1(dsFv)PE38 2Radiotherapy 2Psychiatric Rehabilitation 2Methods 2Interleukin-12 2Gene Expression Profiling 2Gemcitabine 2Filgrastim 2Early Intervention, Educational 2Capecitabine 2Albumin-Bound Paclitaxel 2veliparib 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × sacituzumab govitecan × Gastrointestinal × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡